Last reviewed · How we verify

Darunavir and Cobicistat

Shanghai Public Health Clinical Center · FDA-approved active Small molecule Quality 5/100

Darunavir and Cobicistat is a Small molecule drug developed by Shanghai Public Health Clinical Center. It is currently FDA-approved.

At a glance

Generic nameDarunavir and Cobicistat
SponsorShanghai Public Health Clinical Center
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Darunavir and Cobicistat

What is Darunavir and Cobicistat?

Darunavir and Cobicistat is a Small molecule drug developed by Shanghai Public Health Clinical Center.

Who makes Darunavir and Cobicistat?

Darunavir and Cobicistat is developed and marketed by Shanghai Public Health Clinical Center (see full Shanghai Public Health Clinical Center pipeline at /company/shanghai-public-health-clinical-center).

What development phase is Darunavir and Cobicistat in?

Darunavir and Cobicistat is FDA-approved (marketed).

Related